Cardiff Oncology Discloses Major Clinical Breakthrough Amid 2025 Financial Update

Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company focused on PLK1 inhibition therapies, has disclosed encouraging clinical results and financial outcomes for the full year 2025, marking significant progress in its lead oncology program targeting RAS-mutated metastatic colorectal cancer. The company’s latest announcements underscore advancing clinical efficacy while maintaining operational focus toward regulatory milestone achievement.

Clinical Efficacy Breakthrough in Colorectal Cancer Program

The centerpiece of Cardiff Oncology’s 2025 update involves positive data from the randomized Phase 2 CRDF-004 trial evaluating Onvansertib, the company’s PLK1 inhibitor, in first-line RAS-mutated mCRC. The 30 mg Onvansertib combination with FOLFIRI/bev (standard chemotherapy backbone) demonstrated an objective response rate of 72.2%, substantially outperforming the combined standard-of-care control arms at 43.2%. Beyond response rates, progression-free survival data showed meaningful improvement, with no incremental toxicity signals observed, a critical finding for patient tolerability.

Cardiff Oncology is now advancing this 30 mg dosing regimen into a registrational development pathway, with comprehensive trial data and detailed regulatory strategy expected during the first half of 2026. This progression suggests the company is moving toward pivotal trial initiation in coming months.

Supporting this primary program, investigator-sponsored clinical data presented at the American Society of Hematology (ASH) 2025 conference indicated preliminary efficacy signals in chronic myelomonocytic leukaemia (CMML), with approximately 40% of patients showing clinical benefit, potentially expanding the therapeutic scope of Onvansertib across hematologic malignancies.

Financial Position and Operating Outlook

Royalty revenue streams contributed $0.6 million during 2025, compared to $0.7 million in 2024, reflecting relatively stable non-operating income. Total operating expenses remained essentially flat at $49.6 million versus $49.3 million year-over-year, indicating disciplined cost management during late-stage development preparations.

The net loss for 2025 totaled $45.9 million, or $0.69 per diluted share, improving from the $45.5 million net loss ($0.95 per share) reported in 2024. At year-end, Cardiff Oncology maintained cash, cash equivalents and short-term investments totaling $58.3 million, which management projects will sustain operations into the first quarter of 2027—providing sufficient runway for pivotal trial initiation and advancement.

Leadership Structure and Organizational Changes

To support late-stage clinical and regulatory development, Cardiff Oncology announced executive organizational changes effective January 2026. Mani Mohindru, PhD was appointed interim Chief Executive Officer, while Brigitte Lindsay assumed the role of Chief Accounting Officer. The company has concurrently initiated a comprehensive search for permanent Chief Executive Officer and Chief Financial Officer positions, signaling leadership stability during this critical developmental phase.

Market Performance Context

Over the trailing 12-month period, CRDF shares have fluctuated between $1.48 and $4.86. In recent trading activity, the stock closed at $1.70, reflecting an 8.97% gain, demonstrating market recognition of the clinical and strategic progress disclosed in this comprehensive update.